

Info Sheet for Technical description

No. 0016

Organization

* Mandatory fields

Name of Organization*	RAYMEI INC.	
Address, City, States, Zip, Country*	#D95 Industry-University Co-Creation (Bldg.D), 2-1 Yamada-oka, Suita, Osaka 565-0871, Japan	
URL	https://www.raymei.co.jp/index_en.html	
Brief Descriptions of Organization* (Approx. 100 words)	Mission=Commercialize the results of research on regenerative medicine using iPS cells, etc. at the Department of Ophthalmology, Osaka University School of Medicine, and to develop new treatment methods for ophthalmic diseases and related products. Business Goals=Aim to provide a stable supply of high-quality corneal epithelium and endothelium with minimal rejection using iPS cells for transplantation.	
Contact address	Name*	Yasushi Hiramane
	Department* / Position	Director/Chief Operating Officer
	E-mail* / TEL	yasushi.hiramane@raymei.co.jp

What kind of technology do you want to offer? *

- ☒ **A.** Clinical Development Pipelines → Please see **Sheet [A]**
- ☐ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc. → Please see **Sheet [B]**
- ☐ **C.** Platform Technologies(*) that are not included in the above (Group B) → Please see **Sheet [C]**
- * Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

☒ Yes

☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☒ Series A
- ☐ Series B
- ☐ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	
☐ No	

Filled in by*

Date*

Yasushi Hiramane
2025/7/31

Sheet [A] Clinical Development Pipelines**Info Sheet for Technical overview**

No. A-0016

* Mandatoty fields

Title*human allo-iPSC-derived corneal epithelial cell sheet**Development Phase***

- | | | |
|---|--|---|
| ☐ Basic Research | ☐ Drug Discovery | ☒ Pre-Clinical |
| ☐ Clinical Trial (Phase I) | ☐ Clinical Trial (Phase II) | ☐ Clinical Trial (Phase III) |
| ☐ Review | ☐ Others | |

Diesease Area*

- | | | |
|--|---|---|
| ☐ Cancer | ☐ Central nervous system | ☒ Ophthalmology |
| ☐ Musculoskeletal | ☐ Endocrine / Metabolism | ☐ Cardiovascular |
| ☐ Urogenital | ☐ Digestive organ | ☐ Blood |
| ☐ Infection | ☐ Dermatology | ☐ Immunity |
| ☐ Otolaryngology | ☐ Respiratory | ☐ Others |

Description*

This product is a corneal epithelial cell sheet derived from allogeneic iPS cells and is based on the SEAM method developed by Professor Nishida, Department of Ophthalmology, Osaka University (Hayashi, Nature 2016). Sheets of the same manufacturing method have been suggested to be safe and effective for limbal stem cell deficiency (LSCD) in a clinical study conducted by Osaka University. We are developing iPS cell-derived corneal epithelial cell sheets as a regenerative medicine product and are preparing for clinical trials in Japan.

Filled in by*

Yasushi Hiramine

Date*

2025/7/31